Core Viewpoint - The inclusion of SINO Pharmaceutical-B (2591.HK) in the Hang Seng Composite Index marks a significant recognition of its investment value and lays the groundwork for its future inclusion in the Hong Kong Stock Connect program [1] Group 1: Market Performance and Recognition - SINO Pharmaceutical has demonstrated strong market performance since its listing, achieving a subscription rate of 5340 times during its IPO, making it the second most oversubscribed new stock of the year [2] - The company's stock price surged over 285% on its first trading day and maintained high interest, closing with a 206% increase, reflecting strong market recognition of its core value [2] - Despite experiencing short-term price adjustments due to market sentiment, the company's operational progress aligns with the broader trend of quality stocks in the innovative drug sector recovering in value [2] Group 2: R&D and Competitive Edge - SINO Pharmaceutical's R&D capabilities are a core competitive advantage, particularly in the efficiency of pipeline advancement and source innovation [4] - The company has positioned itself as a leader in the GLP-1 drug market with its product, Isu-Paglutide α, being the first GLP-1 drug approved in Asia and the third globally, showcasing its competitive edge [5] - The drug's long half-life allows for bi-weekly dosing, addressing patient compliance issues, which strengthens its market position [5] Group 3: Commercialization and Market Strategy - The rapid commercialization of Isu-Paglutide α, which generated revenue of 56.446 million yuan by June 30, demonstrates the company's effective commercialization capabilities [6] - The drug has successfully passed the formal review for inclusion in the National Medical Insurance Drug List, which could enhance its market penetration [6][7] - The company has established a robust commercialization team to support market entry and growth following the drug's inclusion in insurance [7] Group 4: Global Expansion and Market Positioning - SINO Pharmaceutical is leveraging its experience in the Greater Bay Area to create a replicable commercialization model for international markets [16] - The company is targeting emerging markets in Southeast Asia and Latin America, where there is a high demand for GLP-1 drugs due to insufficient supply [17][18] - SINO Pharmaceutical is also preparing to enter mainstream markets like Europe and the U.S. by accumulating necessary clinical data through ongoing trials [19] Group 5: Future Outlook and Investment Potential - The global market for anti-obesity drugs is projected to exceed $100 billion by 2030, positioning SINO Pharmaceutical favorably with its differentiated product offerings [21] - The company is expected to benefit from upcoming catalysts such as the results of insurance negotiations, BLA approvals in Southeast Asia, and the completion of clinical trials for obesity indications [21] - Current market conditions may present an opportune moment for investors to consider SINO Pharmaceutical as a key player in the valuation recovery of the Hong Kong pharmaceutical sector [21]

每经AI快讯，银诺医药-B(02591.HK)涨近10%，截至发稿，涨9.81%，报31.8港元，成交额276.93万港 元。 ...

Core Viewpoint - The inclusion of SINO Pharmaceutical-B (2591.HK) in the Hang Seng Composite Index marks a significant recognition of its investment value and lays the foundation for its future inclusion in the Hong Kong Stock Connect [1][2]. Company Performance - SINO Pharmaceutical has demonstrated strong market performance since its listing, achieving a subscription rate of 5340 times during its IPO, making it the second most oversubscribed new stock of the year [2]. - The company's stock price surged over 285% on its first trading day and closed up 206%, reflecting high market recognition of its core value [2]. - Despite experiencing short-term price adjustments due to market sentiment, the company's core operational actions have remained steady, aligning with the logic of prioritizing quality stocks for recovery [2]. Research and Development - SINO Pharmaceutical's R&D capabilities are a key competitive advantage, particularly in pipeline advancement and source innovation [4]. - The company has successfully launched its GLP-1 drug, Isu-Paglutide α, becoming the first in Asia to do so and the third globally, showcasing its leading clinical advancement efficiency [5]. - The drug's long half-life supports bi-weekly dosing, addressing patient compliance issues, which strengthens its competitive position in the market [5]. Market Strategy - The rapid commercialization of Isu-Paglutide α in China, with revenues of 56.446 million yuan by June 30, demonstrates the company's effective commercialization capabilities [6]. - The drug has passed the formal review for inclusion in the National Medical Insurance Drug List, which could enhance its market penetration [6][7]. - The company is expanding its indications for Isu-Paglutide α, with ongoing clinical trials for obesity and metabolic dysfunction-related fatty liver disease (MASH), which broadens its growth potential [7]. Innovation Pipeline - SINO Pharmaceutical has a robust pipeline with five preclinical candidates targeting various diseases, indicating its commitment to true innovation rather than following existing treatments [8][10]. - The company’s new targets are designed to address unmet clinical needs, positioning it for potential industry disruption [10][11]. Global Expansion - The company is building a global presence with a focus on emerging markets, leveraging its clinical data from China to gain regulatory approvals [15][17]. - SINO Pharmaceutical has achieved commercial success in Macau and is applying for BLA in Southeast Asia and Latin America, aiming to capture market share in regions with high unmet medical needs [16][18]. - The company is also preparing for entry into mainstream markets like Europe and the U.S. by accumulating necessary clinical data through ongoing trials [19]. Industry Outlook - The global market for GLP-1 drugs is expected to expand significantly, with projections indicating it could exceed $100 billion by 2030 [21]. - SINO Pharmaceutical's differentiated product offerings and global strategy align with institutional expectations for innovation value pricing [21]. - The company is positioned to benefit from upcoming catalysts, including insurance negotiations and clinical trial milestones, which could enhance its fundamental value [21].

Core Viewpoint - Silver诺医药-B (02591) has seen a nearly 10% increase in stock price following its inclusion in the Hang Seng Composite Index, effective December 8, 2025, which is expected to enhance its market visibility and support its research and commercialization efforts [1] Group 1: Company Developments - As of November 21, Silver诺医药's stock rose by 9.81%, reaching HKD 31.8, with a trading volume of HKD 2.7693 million [1] - The company announced the completion of the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight, with plans to recruit approximately 800 participants [1] Group 2: Product and Market Insights - Shanghai Securities highlighted that Isuparaglutide α demonstrates good safety and efficacy in reducing blood sugar and weight, showing significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] - The GLP-1 sector remains highly competitive, with ongoing attention on the expansion of indications, submission for market approval, and the commercialization process [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 關於董事會及監事會延期換屆的公告 廣州銀諾醫藥集團股份有限公司（「本公司」）第一屆董事（「董事」）會（「董事會」） 及監事會（「監事會」）的任期將於2025年11月22日屆滿。鑒於董事會換屆及監事 會換屆（「換屆」）籌備工作正在進行中，為保持董事會及監事會的連續運作，將延 期換屆，第一屆董事會及第一屆監事會的任期將順延至根據本公司組織章程細則 的規定於股東大會選舉產生新一屆董事會及監事會之日止。同時，本公司各董事 委員會的第一屆任期將相應順延。 於完成換屆之前，第一屆董事會、各董事委員會及第一屆監事會的成員將依照相 關法律、法規及本公司組織章程細則的規定繼續履行彼等之職責。 延期換屆將不會影響本公司的正常運營。本公司將積極推進換屆選舉工作並按照 香港聯合交易所有限公司證券上市規則的相關要求及時履行相應的披露義務。 承董事會命 廣州銀諾醫藥集團股份有限公司 董事長 WANG QINGHUA博士 中國，上海， ...

Summary of Key Points Core Viewpoint - As of November 21, 14 stocks reached their 52-week highs, with Hengfa Optical (01134), Chaowei Holdings (08059), and Cassava Resources (00841) leading the gains at 42.11%, 30.56%, and 22.49% respectively [1]. 52-Week Highs - Hengfa Optical (01134) closed at 0.375, with a peak price of 0.540, marking a 42.11% increase [1]. - Chaowei Holdings (08059) closed at 0.030, reaching a high of 0.047, reflecting a 30.56% rise [1]. - Cassava Resources (00841) closed at 0.200, with a maximum price of 0.207, indicating a 22.49% increase [1]. - Other notable stocks include Sibor Systems (08319) at 15.04%, MOS HOUSE (01653) at 11.46%, and Tianjin Jianfa (02515) at 5.19% [1]. 52-Week Lows - China Pengfei Group (03348) reached a low of 1.100, down 20.09% from its peak [1]. - China Information Technology (08178) closed at 0.285, reflecting a 19.35% decrease [1]. - XL Ernan Strategy - U (09799) saw a decline of 14.27% [1]. - Other significant declines include Hesai - W (02525) at -10.54% and MBC Bitcoin - U (03425) at -9.09% [1]. Additional Notable Stocks - Stocks like MBC Bitcoin (03430) and Tongyuan Kang Pharmaceutical - B (02410) also experienced declines of 6.64% and 6.62% respectively [2]. - The overall trend indicates a mix of significant gains in certain stocks while others are facing substantial losses, reflecting a volatile market environment [1][2].

| 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | ...

Core Viewpoint - Silver诺医药-B (02591.HK) announced the subscription of a structured deposit product from Ningbo Bank for a total consideration of RMB 105 million, which is equivalent to its total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, will invest in the structured deposit product [1] - The total investment amount is RMB 105 million, indicating a significant financial commitment by the company [1]

Core Viewpoint - Silver诺医药-B (02591) announced the subscription of a structured deposit product from Ningbo Bank for a total consideration of RMB 105 million, which is equivalent to its total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, will invest in the structured deposit product [1] - The transaction is set to take place on November 3, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） 本公司及銀諾技術各自認購寧波銀行結構性存款產品透過市場進行，代價以本集 團自有資金支付（為免生疑問，上述資金不涉及本公司因上市而募集的任何所得 款項）。 於本公司及銀諾技術各自認購寧波銀行結構性存款產品前，由於本公司及銀諾技 術於2025年10月14日各自認購的結構性存款產品已於2025年10月30日到期（詳情 請參閱本公司日期為2025年10月14日的公告），概無本集團已認購處於存續期的 寧波銀行金融產品。 （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年11月3日，本公司及銀諾技術（本公司一間直接全資附屬公 司）以代價合共人民幣105,000,000元（即其總本金額）向寧波銀行認購一款結構性 存款產 ...